Open Access
Issue
BioMedicine
Volume 8, Number 4, December 2018
Article Number 26
Number of page(s) 5
DOI https://doi.org/10.1051/bmdcn/2018080426
Published online 26 November 2018
  1. Claes D, Jackson E. Cystinuria: mechanisms and management. Pediatr Nephrol. 2012; 27: 2031–8. [CrossRef] [PubMed] [Google Scholar]
  2. Goodyer P. The Molecular Basis of Cystinuria. Nephron Exp Nephrol. 2004; 98: e45–e49. [CrossRef] [PubMed] [Google Scholar]
  3. Christopher NG, Stevan S. Contemporary Management of Cystinuria. J Endourology. 1999; 13(9): 647–53. [CrossRef] [Google Scholar]
  4. Milliner DS, Murphy ME. Urolithiasis in pédiatrie patients (see comments). Mayo Clin Proc. 1993; 68: 241. [CrossRef] [PubMed] [Google Scholar]
  5. Polinsky MS, Kaiser BA, Blauarte HJ. Urolithiasis in childhood. Pediatr Clin North Am. 1987; 34: 683. [CrossRef] [PubMed] [Google Scholar]
  6. Lee M. cystine growth Inhibition through molecular mimicry: a New Paradigm for the Prevention of Crystal Diseases. Curr Rheumatol Rep. 2015; 17(5): 33. [CrossRef] [PubMed] [Google Scholar]
  7. Gambaro G, Favaro S, D’Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis. 2001; 37(233): 243. [CrossRef] [Google Scholar]
  8. Simfroush N, Alizadeh A. Urology. 2017; 1–100. [Google Scholar]
  9. Evan A, FLCoe F, Lingeman JE. Renal crystal deposit and histopathology in patients with cystin stone. Kidney International. 2006; 69: 2227–35 [CrossRef] [PubMed] [Google Scholar]
  10. Leusmann DB, Niggemann H, Roth S, von Ahlen H. Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol. 1995; 29: 279–83. [CrossRef] [PubMed] [Google Scholar]
  11. Leusmann DB, Blaschke R, Schmandt W. Results of 5035 stone analyses: a contribution to epidemiology of urinary stone disease. Scand J Urol Nephrol. 1990; 24: 205–10. [CrossRef] [PubMed] [Google Scholar]
  12. Harperin E. The Use of D-Penicillamine in Cystinuria: Efficacy and Untoward Reactions. The Year Journal pof biology and medicine. 1981; 54: 439–46. [Google Scholar]
  13. Daudon M, Cohen-Solal F. Cystine crystal volume determination: a useful tool in the management of cystinuric patients. Urol Res. 2003; 31: 207–11. [CrossRef] [PubMed] [Google Scholar]
  14. Sakly R, Chaouch A. Effects of intraperitoneally administered vitamin E and selenium on calcium oxalate renal stone formation: experimental study in rat. Annales d’urologie. 2003; 37: 47–50. [Google Scholar]
  15. Jacob C. Sulfur and Selenium: The role of oxidation state in protein structure and function. Angew. Chem. Int. Ed. 2003; 42: 4742–58. [CrossRef] [Google Scholar]
  16. Knoll T, Zollner A, Wendt-Nordahl G, Michel MS, Alken P. Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. Pediatr Nephrol. [Google Scholar]
  17. Wollaston WH. On cystic oxide, a new species of urinary calculus. Philos Trans R Soc Lond. 1810; 100: 223–30. [CrossRef] [Google Scholar]
  18. Liu Y, Xu H. Wenting Zhong, Qingpeng Shen. Organic Selenium Alleviated the Formation of Ethylene Glycol-Induced Calcium Oxalate Renal Calculi by Improving Osteopontin Expression and Antioxidant Capability in Dogs. Biol Trace Elem Res. 2015; 168: 392400. [Google Scholar]
  19. Slojewski M. Major and trace elements in lithogenesis. Central European Journal of rology. 2011; 64: 2–8. [Google Scholar]
  20. Chrzan P, Ramaswamy K. MP34-06 inhibition of nucleation and growth of cystin crystal in urine. The Journal of Urology. 2015; 193(4s): e412–e413. [CrossRef] [Google Scholar]
  21. Singh V, Pradeep K, Rai P. Kidney stone analysis techniques and the role of major and trace elements on their pathogenesis: a review. Biophys Rev. 2014; 6: 291–310. [CrossRef] [PubMed] [Google Scholar]
  22. Ludwig Strohmaier W. Reduction of high-energy shock-wave- induced renal tubular injury by selenium. Urol Res. 1999; 27: 382–5. [CrossRef] [PubMed] [Google Scholar]
  23. Liu Y, Xu H. Organic Selenium Alleviated the Formation of Ethylene Glycol-Induced Calcium Oxalate Renal Calculi by Improving Osteopontin Expression and Antioxidant Capability in Dogs. Biol Trace Elem Res. 2015; 168: 392–400. [CrossRef] [PubMed] [Google Scholar]
  24. Mani SK, Ramasamy S. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. Nutr Biochem. 2003; 14: 306–13. [CrossRef] [Google Scholar]
  25. Grases F, Garcia FL, Costa BA. Development of calcium oxalate crystals on urothelium effect of free radical. Nephron. 1998; 78: 296–301. [CrossRef] [PubMed] [Google Scholar]
  26. Selvam R. Calcium oxalate stone disease: role of lipid peroxidation and antioxidants. Urol Res. 2002; 30: 35–47. [CrossRef] [PubMed] [Google Scholar]
  27. Adhirai M, Selvam R. Effect of cyclosporin on liver antioxidants and the protective role of vitamin E in hyperoxaluria in rats. Pharm Pharmacol. 1998; 50: 501–5. [CrossRef] [Google Scholar]
  28. Anbazhagan M, Hariprasad C. Samudram P, Latha E, Latha M, Sel- vam R. Effect of oral supplementation of vitamin E on urinary risk factors in patients with hyperoxaluria. Clin Biochem Nutr. 1999; 27: 37–47. [CrossRef] [Google Scholar]
  29. Mani SK, Ramasamy S. Supplementation of vitamin E and selenium prevents hyperoxaluria in experimental urolithic rats. Nutr Biochem. 2003; 14: 306–13. [CrossRef] [Google Scholar]
  30. Thamilselvan S. Menon M Vitamin E therapy prevents hyperoxaluria-induced calcium oxalate crystal deposition in the kidney by improving renal tissue antioxidant status. BJU Int. 2005; 96: 117–26. [CrossRef] [PubMed] [Google Scholar]